NCT04351932 is a Phase 3 clinical trial of bone marrow mesenchymal stem cells in Osteo Arthritis Knee, sponsored by Universidad Catolica Santiago de Guayaquil.

Who is sponsoring NCT04351932?

NCT04351932 is sponsored by Universidad Catolica Santiago de Guayaquil.

What drugs are being tested in NCT04351932?

Interventions in NCT04351932: bone marrow mesenchymal stem cells, Adipose Mesenchymal stem cells, bone marrow & adipose mesenchymal stem cells injection.

What condition does NCT04351932 study?

NCT04351932 studies Osteo Arthritis Knee.

Is NCT04351932 still recruiting?

NCT04351932 is currently status unknown. Last updated 17 April 2020.

Last reviewed 2020-04-17 · How we verify

NCT04351932

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bone Marrow Versus Adipose Autologous Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis

Status unknown Phase 3 Last updated 17 April 2020

What this trial tests

Phase 3 trial testing bone marrow mesenchymal stem cells in Osteo Arthritis Knee in 54 participants. Status unknown.

Timeline

7 June 2020

Primary endpoint
7 June 2021

7 September 2021

Quick facts

Lead sponsor	Universidad Catolica Santiago de Guayaquil
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	7 June 2020
Primary completion	7 June 2021
Estimated completion	7 September 2021
Sites	1 location across Ecuador

Drugs / interventions tested

bone marrow mesenchymal stem cells — full drug profile →
Adipose Mesenchymal stem cells — full drug profile →
bone marrow & adipose mesenchymal stem cells injection — full drug profile →

Conditions studied

Osteo Arthritis Knee — all drugs for Osteo Arthritis Knee →

Sponsor

Universidad Catolica Santiago de Guayaquil — full company profile →

Who can join

Adults 18 to 70, any sex, with Osteo Arthritis Knee. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mesenchymal stem cells (MSC) are stromal cells that have the ability to self-renew and also exhibit multilineage differentiation. MSCs can be isolated from a variety of tissues, such as umbilical cord, bone marrow, and adipose tissue. The multipotent properties of MSCs make them a promising option for the treatment of osteoarthritis (OA). Bone marrow mesenchymal stem cells (BM-MSC) and adipose derived mesenchymal stem cells (AD-MSC) have been used separately to treat OA. The aim of the present study will be to compare in a randomized non blind controlled clinical trial 3 types of intra-articular injections containing MSC populations obtained from two clinically relevant sources: BM-MSC, AD-MSC and a combination of both BM-MSC and AD-MSC.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders.
Markov A, Thangavelu L, Aravindhan S, Zekiy AO, et al · · 2021 · cited 174× · PMID 33736695 · DOI 10.1186/s13287-021-02265-1
Cell-based therapy in the treatment of musculoskeletal diseases.
Trapana J, Weinerman J, Lee D, Sedani A, et al · · 2024 · cited 18× · PMID 39226104 · DOI 10.1093/stcltm/szae049
Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments.
Vrouwe JPM, Burggraaf J, Kloppenburg M, Stuurman FE. · · 2021 · cited 16× · PMID 36474768 · DOI 10.1016/j.ocarto.2021.100212
Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options.
Mello DB, Mesquita FCP, Silva Dos Santos D, Asensi KD, et al · · 2024 · cited 15× · PMID 38892249 · DOI 10.3390/ijms25116063
The Progress of Stem Cell Technology for Skeletal Regeneration.
Tani S, Okada H, Chung UI, Ohba S, et al · · 2021 · cited 7× · PMID 33573345 · DOI 10.3390/ijms22031404

Verify or expand the search:

Other recruiting trials for Osteo Arthritis Knee

Currently open trials in the same condition.

NCT07258693 — Multimodal Treatment of Knee Osteoarthritis: Therapeutic Exercise and Noninvasive Neuromodulation (NESA) Versus Therapeu · NA · active not recruiting
NCT07141316 — Effects of Blood Flow Restriction Combined With Electrostimulation After Knee Arthroplasty · NA · active not recruiting
NCT06485843 — An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Jo · Phase 2 · recruiting
NCT06965946 — Intermittent Hypoxia-Hyperoxia Combined With Physical Therapy for Knee Osteoarthritis · NA · recruiting
NCT06058169 — Effects of Home Base Whole-body Vibration in Osteoarthritis. (VIBE-Rx2) · NA · recruiting

Other Universidad Catolica Santiago de Guayaquil trials

Trials by the same sponsor.

NCT07484685 — Reduced Time Interval for Implant Placement After Extraction Socket Preservation Using the Vega Plus Implants · NA · not yet recruiting
NCT06501729 — Kissing as a Protective Factor Against Acidic pH in Saliva · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04351932 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidad Catolica Santiago de Guayaquil
Last refreshed: 17 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04351932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing